Interleukin 28B Polymorphism Predicts Pegylated Interferon Plus Ribavirin Treatment Outcome in Chronic Hepatitis C Genotype 4
Stella De Nicola(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Massimo Colombo(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Raffaele De Francesco(Istituto Nazionale Genetica Molecolare), Maria Francesca Donato(University of Milan), Luca Valenti(University of Verona), E. Galmozzi(University of Milan), Roberta D’Ambrosio(University of Southern California), Alessio Aghemo, Maria Grazia Rumi(University of Milan), R. Soffredini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Gian Maria Prati(University of Milan), Cristina Cheroni(Istituto Nazionale Genetica Molecolare)
Cited by 83
Related Papers
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Hepatology|2023|2.9k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Journal of Hepatology|2023|2.7k
EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
|Journal of Hepatology|2024|1.6k
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
|Annals of Hepatology|2023|789